The Journal of Immunology · 2000 · 42 citations · 45 references
Life SciencesImmunologyInfectious DiseasesCellular ImmunologyImmunology Of Infectious DiseasesImmunoregulationAdaptive Immune ResponsesAntiretroviral TherapyCell-mediated ImmunityCellular Immunity In InfectionT Cell ActivationT Cell BiologyCd4 Positive T Cell ResponsesCd4 Positive T CellsCellular Immune Response To VirusesHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyHiv-associated ImmunosuppressionT-cell Immune ResponsesViral Immune Responses
It has been suggested that CD4+ T cell proliferative responses to HIV p24 Ag may be important in the control of HIV infection. However, these responses are minimal or absent in many HIV-infected individuals. Furthermore, while in vitro and in vivo responses to non-HIV recall Ags improve upon administration of highly active antiretroviral therapy, there does not appear to be a commensurate enhancement of HIV-specific immune responses. It is possible that CD4+ p24-specific T cells are deleted early in the course of infection. However, it is also possible that a discrete unresponsiveness, or anergy, contributes to the lack of proliferation to p24. To evaluate the possible contribution of unresponsiveness to the lack of CD4+ T cell proliferation to p24 in HIV-infected individuals, we attempted to overcome unresponsiveness. CD40 ligand trimer (CD40LT) and IL-12 significantly increased PBMC and CD4+ T cell proliferative responses to p24 Ag in HIV-infected, but not uninfected, individuals. No increase in proliferative response to CMV Ag was observed. CD40LT exerted its effect through B7-CD28-dependent and IL-12- and IL-15-independent mechanisms. Finally, the increase in proliferation with CD40LT and IL-12 was associated with an augmented production of IFN-gamma in most, but not all, individuals. These data suggest the possible contribution of HIV-specific unresponsiveness to the lack of CD4+ T cell proliferation to p24 Ag in HIV-infected individuals and that clonal deletion alone does not explain this phenomenon. They also indicate the potential for CD40LT and IL-12 as immune-based therapies for HIV infection.
45
Federica Sallusto, Antonio Lanzavecchia · The Journal of Experimental Medicine · 1994 · 5.2K citations · Full text
Marina Cella, Doris Scheidegger, Kathrin Palmer-Lehmann et al. · The Journal of Experimental Medicine · 1996 · 2K citations · Full text